Successful treatment of an elderly patient with lung squamous cell carcinoma by tislelizumab and chemotherapy: a case report with novel imaging findings
The advent of immunotherapy has transformed the therapeutic landscape for inoperable, locally advanced Non-Small cell lung cancer (NSCLC), particularly for lung squamous cell carcinoma (LUSC) with a predominance of negative driver genes. Based on the results of clinical trials such as KEYNOTE-042 an...
Saved in:
| Main Authors: | Lufan Xu, Xinxin Ma, Yang Yang, Zhiqiang Ding, Yi Luo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1543114/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study
by: Qi Zhao, et al.
Published: (2025-08-01) -
Corrigendum: Case report: Multi-organ injuries induced by tislelizumab
by: Man Yuan, et al.
Published: (2025-06-01) -
Successful treatment of recurrent unresectable squamous cell carcinoma of the head and neck using pembrolizumab
by: A. M. Mudunov, et al.
Published: (2019-04-01) -
Efficacy and safety of Tislelizumab combined with Axitinib as first-line treatment for intermediate- and high-risk metastatic clear-cell renal cell carcinoma
by: Jie Cui, et al.
Published: (2025-05-01) -
Cost-effectiveness analysis of tislelizumab plus chemotherapy as first-line treatment for HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma
by: Liangliang Zou, et al.
Published: (2025-05-01)